Immunovant Inc., of New York, finished its previously disclosed public offering, including the full exercise of the underwriters’ option to purchase added shares, for gross proceeds of about $139.4 million.
Lantern Pharma Inc., of Dallas, filed to raise up to $29 million in an IPO. No pricing terms were disclosed. The oncology-focused company, which uses artificial intelligence to advance precision therapeutics, plans to list on Nasdaq under the ticker LTRN. Thinkequity and Dougherty & Co. are the joint bookrunners.
Neurobo Pharmaceuticals Inc., of Boston, finished its previously disclosed registered direct offering of 750,000 shares of its common stock at a price of $10 each for gross proceeds of about $7.5 million. The company intends to use the net proceeds for working capital, capital expenditures and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Pulmatrix Inc., of Lexington, Mass., signed definitive agreements with several institutional and accredited investors for the purchase and sale of about 4.7 million shares of the company's common stock, at a purchase price of about $1.67 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Pulmatrix has also agreed to issue to the investors unregistered warrants to purchase up to about 4.7 million shares of common stock. The closing of the offering is expected to occur on or about April 20. H.C. Wainwright & Co. is acting as the exclusive placement agent.